Cellserach is the first and only actionable test for detecting CTCs in cancer patients with metastatic breast, prostate* or colorectal cancer.
Cellsearch is :
- The first and only clinically validated, FDA-cleared blood test for enumerating circulating tumor cells (CTCs). CTCs are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body.
- This is a “liquid biopsy” that can be used at any time during a patient’s course of disease.
The CELLSEARCH® CTC Test is a simple, actionable blood test that helps oncologists assess the prognosis of patients with metastatic breast, prostate*, or colorectal cancer. Tumors metastasize, or spread, when they detach from the primary tumor and enter into the bloodstream, which in turn transports the cells to distant sites, such as bones, liver, brain, and lungs. Tumor cells detected in the blood stream are referred to as CTCs. Once they have traveled to a distant site, some of these cells may establish new tumors in these sites, a process known as metastasis. CTCs are rarely found in healthy people or in people with nonmalignant tumors. Among 295 healthy controls (with or without benign tumors), only 3% had >1 CTC detected in blood samples analyzed by the CELLSEARCH® Circulating Tumor Cell Test.
